Why should we need the gut microbiota to respond to cancer therapies?

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Viaud, Sophie ^a,b   Daillère, Romain ^a,b   Yamazaki, Takahiro ^a   Lepage, Patricia ^c   Boneca, Ivo ^a,d   Goldszmid, Romina ^e   Trinchieri, Giorgio ^e   Zitvogel, Laurence ^a,b,f  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UMR1319 MICALIS   (France)

^d INSTITUT PASTEUR   (France)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Centre d'Investigation Clinique Biothérapie CICBT 507 Gustave Roussy   (France)

Author keywords

Antibiotics; Cancer; Chemotherapy; Gram positive bacteria; Immunomodulatory regimen; Microbiota; PTh17

Indexed keywords

CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR3; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 17; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR T BET; TUMOR ANTIGEN;

ARTICLE; CANCER CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CELL POLARITY; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; DRUG RESPONSE; EFFECTOR CELL; HELPER CELL; HUMAN; INTESTINE FLORA; MEMORY T LYMPHOCYTE; NONHUMAN; TH1 CELL; TH17 CELL;

EID: 84899115485     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27574     Document Type: Article

References (10)

1. Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 2011; 9:279-90; PMID:21407244; http://dx.doi.org/10.1038/nrmicro2540.
2. Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancer. JAMA 2004; 291:827-35; PMID:14970061; http://dx.doi.org/10.1001/jama.291.7.827.
3. Rossini A, Rumio C, Sfondrini L, Tagliabue E, Morelli D, Miceli R, Mariani L, Palazzo M, Ménard S, Balsari A. Influence of antibiotic treatment on breast carcinoma development in proto-neu transgenic mice. Cancer Res 2006; 66:6219-24; PMID:16778196; http://dx.doi.org/10.1158/0008-5472.CAN-05-4592.
4. van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog 2010; 6:e1000879; PMID:20523891; http://dx.doi.org/10.1371/journal.ppat.1000879.
5. Walter S, Weinschenk T, Reinhardt C, Singh-Jasuja H. Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. Oncoimmunology 2013; 2:e22246; PMID:23482454; http://dx.doi.org/10.4161/onci.22246.
6. Kaluza KM, Vile R. Improving the outcome of adoptive cell transfer by targeting tumor escape. Oncoimmunology 2013; 2:e22059; PMID:23483796; http://dx.doi.org/10.4161/onci.22059.
7. Kandalaft LE, Powell DJ Jr., Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013; 2:e22664; PMID:23482679; http://dx.doi. org/10.4161/onci.22664.
8. Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, Soria JC, Marty V, Vielh P, Robert C, et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res 2011; 71:661-5; PMID:21148486; http://dx.doi.org/10.1158/0008-5472.CAN-10-1259.
9. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342:971-6; PMID:24264990; http://dx.doi.org/10.1126/science.1240537.
10. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342:967-70; PMID:24264989; http://dx.doi.org/10.1126/science.1240527.